Shortage of raw material holding up Covovax manufacturing - Hindustan Times
close_game
close_game

Shortage of raw material holding up Covovax manufacturing

ByDivya Rajagopal, New Delhi
Jun 17, 2021 07:55 AM IST

The delay in receiving raw materials such as bioreactor bags and enzymes means that SII’s launch of the Novavax vaccine, branded as Covovax in India, will not likely happen before September this year as planned originally

Serum Institute of India (SII) is yet to receive raw materials from the US needed to produce the Novavax vaccine despite diplomatic interventions by India, said an official aware of the development.

SII is the manufacturing partner for Novavax in India(REUTERS)
SII is the manufacturing partner for Novavax in India(REUTERS)

The delay in receiving raw materials such as bioreactor bags and enzymes means that SII’s launch of the Novavax vaccine, branded as Covovax in India, will not likely happen before September this year as planned originally, the official said, requesting anonymity.

Hindustan Times - your fastest source for breaking news! Read now.

The company said raw material shortages have led to the delay in launching the vaccine.

The US lifted the export ban on raw materials on June 4.

“It’s fair to say that we are far ahead of where anyone thought we would be in our fight against the virus. And, importantly, we have secured enough vaccine supply for all Americans... As a result, we are removing the DPA priority ratings for AstraZeneca, Novavax and Sanofi. While the manufacturers will continue to make these vaccines, the action will allow US-based firms that supply to these manufacturers to make their decisions on the orders to fulfil first,” the White House said on June 2.

The relaxation of the Defence Production Act (DPA) was seen as a direct result of diplomatic talks between India and US with India’s foreign minister S. Jaishankar visiting Washington to appeal to the Joe Biden administration to iron out issues of vaccine distribution and other medical supplies to India.

A spokesperson for SII did not respond to emailed queries.

Earlier, US vaccine maker Novavax announced that its Covid-19 vaccine demonstrated 90% efficacy in phase 3 trials.

SII is the manufacturing partner for Novavax in India where the firm has committed to producing up to 1 billion doses. SII, the world’s largest vaccine maker, has been faltering on its international commitments.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away!- Login Now!
Stay informed on Business News along with Gold Rates Today, India News and other related updates on Hindustan Times Website and APPs
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, March 28, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On